B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CAMK1

MOLECULAR TARGET

calcium/calmodulin dependent protein kinase I

UniProt: Q14012NCBI Gene: 853619 compounds

CAMK1 (calcium/calmodulin dependent protein kinase I) is targeted by 19 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CAMK1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1tofacitinib4.65104
2foretinib4.3476
3tozasertib4.3375
4ruxolitinib4.2368
5midostaurin3.8546
6pazopanib3.6939
7nintedanib3.6136
8tae 6843.4330
9fedratinib3.4029
10sp 6001253.2224
11lestaurtinib3.0420
12r 4062.8316
13pha 6657522.7114
14plx 47202.7114
15kw 24492.6413
16ast 4872.5612
17su 0148132.208
18pictilisib0.691
19sp6001250.691

About CAMK1 as a Drug Target

CAMK1 (calcium/calmodulin dependent protein kinase I) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 19 compounds with documented CAMK1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CAMK1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.